Bora Pharmaceuticals Co., Ltd. (TPE:6472)
Taiwan
· Delayed Price · Currency is TWD 452.50
-32.50 (-6.70%)
At close: Mar 9, 2026
Bora Pharmaceuticals Revenue
Bora Pharmaceuticals had revenue of 4.81B TWD in the quarter ending September 30, 2025, a decrease of -4.40%. This brings the company's revenue in the last twelve months to 21.10B, up 36.05% year-over-year. In the year 2024, Bora Pharmaceuticals had annual revenue of 19.25B with 35.53% growth.
Revenue (ttm)
21.10B
Revenue Growth
+36.05%
P/S Ratio
2.66
Revenue / Employee
n/a
Employees
n/a
Market Cap
56.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 19.25B | 5.05B | 35.53% |
| Dec 31, 2023 | 14.20B | 3.71B | 35.31% |
| Dec 31, 2022 | 10.49B | 5.59B | 114.18% |
| Dec 31, 2021 | 4.90B | 3.10B | 172.28% |
| Dec 31, 2020 | 1.80B | 270.35M | 17.68% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 18.66B |
| Center Laboratories | 1.52B |
| TTY Biopharm Company | 6.50B |
| Grape King Bio | 10.25B |
| ScinoPharm Taiwan | 3.16B |
| Synmosa Biopharma | 6.11B |
| YungShin Global Holding | 8.37B |
| PharmaEssentia | 15.63B |